England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Roche's Gazyva/Gazyvaro Significantly Reduces Disease Activity in the Most Common Form of Lupus
March 07, 2026
March 07, 2026
BASEL, Switzerland, March 7 (TNSjou) -- Roche, a biotech company, issued the following news release on March 6, 2026:
* * *
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche's Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
* Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease seve . . .
* * *
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche's Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
* Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease seve . . .